Hologic Announces Financial Results for First Quarter of Fiscal 2021

Rhea-AI Summary

Hologic reported an impressive financial performance for the fiscal Q1 ended December 26, 2020, with revenues soaring by 89.3% to $1.61 billion. The growth was driven by a 457.6% surge in molecular diagnostics revenue, fueled by demand for SARS-CoV-2 tests. The company also announced acquisitions of Biotheranostics and SOMATEX, with cash flow from operations at $650 million. Although net income rose to $654.4 million, net margins declined by 480 bps. Hologic expects continued strong performance for Q2 with guidance of $1.50 - $1.56 billion in revenue.

Positive

• Revenue increased by 89.3% to $1.61 billion in Q1.
• Molecular diagnostics revenue surged by 457.6% to $995.3 million.
• Organic revenue growth of 107.0% highlights robust business expansion.
• Successful acquisitions of Biotheranostics and SOMATEX to enhance product offerings.
• Operating margin improved to 55.0%, up 4,030 bps from the previous year.

Negative

• Net margin declined by 480 bps to 40.6%.
• U.S. Blood Screening revenue fell by 32.5%.

Hologic, Inc. (Nasdaq: HOLX) announced today the Company’s financial results for the fiscal first quarter ended December 26, 2020.

“Hologic had a strong start to fiscal 2021 across all our businesses and major geographies,” said Steve MacMillan, the Company’s Chairman, President and Chief Executive Officer. “Our Diagnostics division continued to deliver incredible performance by making a massive impact against COVID-19. Furthermore, our Breast Health and Surgical businesses continued to strengthen, with each returning to growth in the United States, Europe and Asia-Pacific.”

Recent Highlights

• Revenue increased 89.3% for the quarter, or 86.5% in constant currency, including revenue from the divested Medical Aesthetics business in the prior year period. Excluding material acquisitions and divestitures, organic revenue in the first quarter increased 107.0%, or 104.0% in constant currency.
• Worldwide molecular diagnostics revenue of $995.3 million increased 457.6%, or 448.7% in constant currency, exceeding expectations based on increased production of, and strong global demand for, the Company’s two SARS-CoV-2 assays that run on the fully automated Panther® and Panther Fusion® systems.
• In early January, announced an agreement to acquire Biotheranostics, a privately held, commercial-stage company that provides molecular diagnostic tests for breast and metastatic cancers, for approximately $230 million.
• On December 31, completed the acquisition of SOMATEX Medical Technologies GmbH, a leader in biopsy site markers and localization technologies, for approximately $64 million.
• Recent regulatory clearances:
  • U.S. FDA clearance of Genius AI™ detection technology, a deep learning-based software designed to help radiologists detect subtle potential cancers in breast tomosynthesis images.
  • U.S. FDA approval of a diagnostic claim for the Company’s Aptima® HIV-1 Quant Dx viral load monitoring assay, making it the first dual-claim assay for both diagnosis and viral load monitoring in the United States.
  • European CE Mark of the Genius™ digital diagnostics system, the first digital cytology platform to combine a new artificial intelligence algorithm with advanced digital imaging to help identify cancerous and pre-cancerous cells in women.
• Cash flow from operations was $650.0 million in the quarter. Based on this strong cash flow, the Company announced the Biotheranostics and SOMATEX acquisitions, repaid $250 million of debt under its revolving credit facility, and repurchased 1.5 million shares of its common stock for $101 million.

Key financial results for the fiscal first quarter are shown in the table below.

		GAAP				Non-GAAP
		Q1’21	Q1’20	Change Increase (Decrease)		Q1’21	Q1’20	Change Increase (Decrease)
Revenues		$1,609.8	$850.5	89.3%		$1,609.8	$850.5	89.3%
Gross Margin		73.3%	51.0%	2,230 bps		77.2%	61.6%	1,560 bps
Operating Expenses		$294.9	$309.0	(4.6%)		$274.5	$289.3	(5.1%)
Operating Margin		55.0%	14.7%	4,030 bps		60.2%	27.5%	3,270 bps
Net Margin		40.6%	45.4%	(480 bps)		46.6%	19.3%	2,730 bps
Diluted EPS		$2.50	$1.43	74.8%		$2.86	$0.61	368.9%

Throughout this press release, all dollar figures are in millions, except EPS, unless otherwise noted. Some totals may not foot due to rounding. Unless otherwise noted, all results are compared to the corresponding prior year period. Non-GAAP results exclude certain cash and non-cash items as discussed under “Use of Non-GAAP Financial Measures.” Constant currency percentage changes show current period revenue results as if the foreign exchange rates were the same as those in the prior year period. Organic revenue is on a constant currency basis and excludes the divested Blood Screening and Medical Aesthetics businesses, as well as the acquired Acessa business.

Revenue Detail
						Increase (Decrease)
$ in millions		Q1’21		Q1’20		Global Reported Change		Global Constant Currency Change		U.S. Reported Change		International Reported Change		International Constant Currency Change
Diagnostics
Cytology & Perinatal		$124.8		$121.0		3.1%		1.1%		3.3%		2.8%		(2.9%)
Molecular Diagnostics		$995.3		$178.5		457.6%		448.7%		375.2%		779.8%		736.1%
Blood Screening		$8.1		$12.0		(32.5%)		(32.5%)		(32.5%)		N/A		N/A
Total Diagnostics		$1,128.2		$311.5		262.2%		256.3%		229.6%		356.3%		333.4%
Excluding Blood		$1,120.1		$299.5		274.0%		267.8%		243.9%		356.3%		333.4%
Breast Health
Breast Imaging		$267.7		$274.8		(2.6%)		(3.7%)		(3.1%)		(1.1%)		(5.7%)
Interventional Breast Solutions		$65.0		$56.3		15.5%		14.6%		17.2%		7.1%		0.9%
Total Breast Health		$332.7		$331.1		0.5%		(0.6%)		0.7%		(0.1%)		(4.9%)
Medical Aesthetics*		$0.0		$65.3		N/A		N/A		N/A		N/A		N/A
GYN Surgical		$124.0		$119.1		4.1%		3.3%		2.3%		13.1%		8.2%
Skeletal Health		$24.9		$23.5		6.0%		4.0%		1.2%		14.4%		8.8%
Total		$1,609.8		$850.5		89.3%		86.5%		79.8%		116.7%		106.0%
Excluding divested Blood and Aesthetics businesses		$1,601.7		$773.2		107.2%		104.1%		91.5%		157.5%		144.7%
Excluding divestitures and Acessa acquisition (organic)		$1,600.4		$773.2		107.0%		104.0%		91.3%		157.5%		144.7%

* Hologic completed the divestiture of its Medical Aesthetics business on December 30, 2019.

Other Financial Highlights

• U.S. revenue of $1,137.8 million increased 79.8%. International revenue of $472.0 million increased 116.7%, or 106.0% in constant currency. Organically, U.S. revenue of $1,128.4 million increased 91.3%, while international revenue of $472.0 million increased 157.5%, or 144.7% in constant currency.
• GAAP gross margin of 73.3% increased 2,230 basis points. Non-GAAP gross margin of 77.2% increased 1,560 basis points, primarily due to sales of SARS-CoV-2 tests and the divestiture of the lower margin Medical Aesthetics business.
• GAAP operating margin of 55.0% increased 4,030 basis points. Non-GAAP operating margin of 60.2% increased 3,270 basis points, primarily due to sales of SARS-CoV-2 tests and the divestiture of the lower margin Medical Aesthetics business.
• GAAP net income attributable to Hologic of $654.4 million increased 69.5%. Non-GAAP net income attributable to Hologic of $749.6 million increased 356.8%. Adjusted non-GAAP earnings before interest, taxes, depreciation and amortization (EBITDA) was $1,000.7 million, an increase of 282.1%.
• Total principal debt outstanding at the end of the first quarter was $2.8 billion. The Company ended the quarter with cash and equivalents of $868.7 million, and a net leverage ratio (net debt over adjusted EBITDA) of 0.8 times.
• On a trailing 12 months basis, adjusted Return on Invested Capital (ROIC) of 26.7% increased 1,440 basis points compared to the prior year period.

Financial Guidance for the Second Quarter of Fiscal 2021

“We expect our strong financial performance to continue in the second quarter of fiscal 2021,” said Karleen Oberton, Hologic’s Chief Financial Officer.

Hologic’s financial guidance for the second quarter of fiscal 2021 is shown in the table below. The guidance is based on a non-GAAP tax rate of approximately 21.75%, and diluted shares outstanding of 262 to 263 million for the quarter. Constant currency guidance assumes that foreign exchange rates are the same in fiscal 2021 as in fiscal 2020. Current guidance assumes that recent foreign exchange rates persist for all of the second quarter of fiscal 2021. Organic revenue guidance is on a constant currency basis and excludes the divested Blood Screening and the acquired Acessa businesses. The guidance does not include the impact of the pending Biotheranostics acquisition, which has not closed.

	Guidance for the Second Quarter of Fiscal 2021
	Guidance $		Reported % Increase (Decrease)		Constant Currency % Increase (Decrease)		Organic % Increase (Decrease)
Q2 2021
Revenue	$1,500 - $1,560		98.4% to 106.3%		93.9% - 101.9%		96.2% - 104.3%
GAAP EPS	$2.34 - $2.46		550.0% - 583.3%
Non-GAAP EPS	$2.56 - $2.68		349.1% - 370.2%

Use of Non-GAAP Financial Measures

The Company has presented the following non-GAAP financial measures in this press release: constant currency revenues; organic revenues; non-GAAP gross margin; non-GAAP operating expenses; non-GAAP operating margin; non-GAAP effective tax rate; non-GAAP net income; non-GAAP net margin; non-GAAP EPS; and adjusted EBITDA. The Company defines its non-GAAP net income, EPS, and other non-GAAP financial measures to exclude, as applicable: (i) the amortization of intangible assets and impairment of goodwill, intangible assets and equipment; (ii) accelerated depreciation related to consolidation and closure of facilities; (iii) additional expenses resulting from the purchase accounting adjustment to record inventory at fair value and adjustments to contingent consideration; (iv) restructuring and divestiture charges and facility closure and consolidation charges and costs incurred to integrate acquisitions (including retention, transaction bonuses, legal and professional consulting services) and separate divested businesses from existing operations; (v) expenses related to its divested Cynosure business incurred subsequent to the disposition date primarily related to indemnification provisions for legal and tax matters; (vi) transaction related expenses for divestitures and acquisitions; (vii) third-party expenses incurred related to implementing the European MDR/IVDR requirements and obtaining the appropriate approvals for its existing products; (viii) debt extinguishment losses and related transaction costs; (ix) the unrealized (gains) losses on the mark-to-market of forward foreign currency contracts and foreign currency option contracts for which the Company has not elected hedge accounting; (x) litigation settlement charges (benefits) and non-income tax related charges (benefits); (xi) other-than-temporary impairment losses on investments and realized gains and losses resulting from the sale of investments; (xii) the one-time discrete impacts related to internal restructuring and non-operational items; (xiii) other one-time, non-recurring, unusual or infrequent charges, expenses or gains that may not be indicative of the Company's core business results; and (xiv) income taxes related to such adjustments. The Company defines adjusted EBITDA as its non-GAAP net income plus net interest expense, income taxes, and depreciation and amortization expense included in its non-GAAP net income. The Company defines organic revenue to exclude the divested Blood Screening and Medical Aesthetic businesses, and the acquired Acessa business.

These non-GAAP financial measures should be considered supplemental to, and not a substitute for, financial information prepared in accordance with GAAP. The company's definition of these non-GAAP measures may differ from similarly titled measures used by others.

The non-GAAP financial measures used in this press release adjust for specified items that can be highly variable or difficult to predict. The company generally uses these non-GAAP financial measures to facilitate management's financial and operational decision-making, including evaluation of Hologic's historical operating results, comparison to competitors' operating results and determination of management incentive compensation. These non-GAAP financial measures reflect an additional way of viewing aspects of the company's operations that, when viewed with GAAP results and the reconciliations to corresponding GAAP financial measures, may provide a more complete understanding of factors and trends affecting Hologic's business.

Because non-GAAP financial measures exclude the effect of items that will increase or decrease the company's reported results of operations, management strongly encourages investors to review the company's consolidated financial statements and publicly filed reports in their entirety. A reconciliation of the non-GAAP financial measures to the most directly comparable GAAP financial measures is included in the tables accompanying this release.

Conference Call and Webcast

Hologic’s management will host a conference call at 4:30 p.m. ET today to discuss its financial results for the first quarter of fiscal 2021. Approximately 10 minutes before the call, dial 888-204-4368 (in the U.S. and Canada) or +1 323-994-2093 (international) and enter access code 2632110. A replay will be available approximately two hours after the call ends through Friday, February 26, 2021. The replay numbers are 888-203-1112 (U.S.) or +1 719-457-0820 (international), access code 2632110, PIN 7018. The Company will also provide a live webcast of the call at investors.hologic.com

About Hologic, Inc.

Hologic, Inc. is an innovative medical technology company primarily focused on improving women's health and well-being through early detection and treatment. For more information on Hologic, visit www.hologic.com.

Hologic and associated logos are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries.

Forward-Looking Statements

This news release contains forward-looking information that involves risks and uncertainties, including statements about the Company’s plans, objectives, expectations and intentions. Such statements include, without limitation: financial or other information based upon or otherwise incorporating judgments or estimates relating to future performance, events or expectations; the Company’s strategies, positioning, resources, capabilities, and expectations for future performance; and the Company's outlook and financial and other guidance. These forward-looking statements are based upon assumptions made by the Company as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those anticipated.

Risks and uncertainties that could adversely affect the Company’s business and prospects, and otherwise cause actual results to differ materially from those anticipated, include without limitation: the severity and duration of the COVID-19 pandemic and its impact on the U.S. healthcare system, the U.S. economy and worldwide economy; the timing, scope and effect of further U.S. and international governmental, regulatory, fiscal, monetary and public health responses to the COVID-19 pandemic; continued demand for the Company’s COVID-19 TMA assay; the Company’s ability to manufacture, on a scale necessary to meet demand, its COVID-19 TMA assay as well as the Panther systems on which the assay runs; U.S., European and general worldwide economic conditions, trade relations, and related uncertainties; manufacturing risks, including the Company’s reliance on a single or limited source of supply for key components, the need to comply with especially high standards for the manufacture of many of its products and risks associated with utilizing third party manufacturers; the Company’s ability to predict accurately the demand for its products, and products under development, and to develop strategies to address its markets successfully; the ability of the Company to successfully manage leadership and organizational changes, including the ability of the Company to attract, motivate and retain key employees and maintain engagement and efficiency in remote work environments; the Company’s reliance on third-party reimbursement policies to support the sales and market acceptance of its products, including the possible adverse impact of government regulation and changes in the availability and amount of reimbursement and uncertainties for new products or product enhancements; changes to applicable laws and regulations, including tax laws, global health care reform, and import/export trade laws; changes in guidelines, recommendations and studies published by various organizations that could affect the use of the Company’s products; uncertainties inherent in the development of new products and the enhancement of existing products, including FDA approval and/or clearance and other regulatory risks, technical risks, cost overruns and delays; the risk that products may contain undetected errors or defects or otherwise not perform as anticipated; risks associated with strategic alliances and the ability of the Company to realize anticipated benefits of those alliances; risks associated with acquisitions, including, without limitation, the Company’s ability to successfully integrate acquired businesses, the risks that the acquired businesses may not operate as effectively and efficiently as expected even if otherwise successfully integrated, and the risks that acquisitions may involve unexpected costs or unexpected liabilities; the risks of conducting business internationally; the risk of adverse exchange rate fluctuations on the Company’s international activities and businesses; the early stage of market development for certain of the Company’s products; the Company’s leverage risks, including the Company’s obligation to meet payment obligations and financial covenants associated with its debt; cybersecurity risks; risks related to the use and protection of intellectual property; expenses, uncertainties and potential liabilities relating to litigation, including, without limitation, commercial, intellectual property, employment and product liability litigation; technical innovations that could render products marketed or under development by the Company obsolete; and competition.

The risks included above are not exhaustive. Other factors that could adversely affect the Company's business and prospects are described in the filings made by the Company with the SEC, including its most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such statements are based.

SOURCE: Hologic, Inc.

HOLOGIC, INC. CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Unaudited) (In millions, except number of shares, which are reflected in thousands, and per share data)
		Three Months Ended
		December 26, 2020					December 28, 2019
Revenues:
Product		$	1,455.4				$	699.3
Service and other		154.4					151.2
Total revenues		1,609.8					850.5
Cost of revenues:
Product		284.5					237.5
Amortization of acquired intangible assets		61.6					63.6
Impairment of intangible assets and equipment		—					25.8
Service and other		83.3					89.8
Gross profit		1,180.4					433.8
Operating expenses:
Research and development		59.3					61.2
Selling and marketing		128.0					144.9
General and administrative		91.5					87.6
Amortization of acquired intangible assets		10.1					9.1
Impairment of intangible assets and equipment		—					4.4
Contingent consideration fair value adjustments		4.6					0.9
Restructuring and divestiture charges		1.4					0.9
Total operating expenses		294.9					309.0
Income from operations		885.5					124.8
Interest income		0.4					2.1
Interest expense		(28.1		)			(32.8		)
Debt extinguishment loss		(21.6		)			—
Other income (expense), net		(3.8		)			3.3
Income before income taxes		832.4					97.4
Provision (benefit) for income taxes		179.0					(288.4		)
Net income		$	653.4				$	385.8
Net loss attributable to noncontrolling interest		(1.0		)			(0.3		)
Net income attributable to Hologic		654.4					386.1
Net income per common share attributable to Hologic:
Basic		$	2.53				$	1.44
Diluted		$	2.50				$	1.43
Weighted average number of shares outstanding:
Basic		258,605					267,893
Diluted		261,785					269,721

HOLOGIC, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (In millions)
		December 26, 2020				September 26, 2020
ASSETS
Current assets:
Cash and cash equivalents		$	868.7			$	701.0
Accounts receivable, net		1,216.1				1,028.9
Inventories		420.2				395.1
Other current assets		91.3				97.3
Total current assets		2,596.3				2,222.3
Property, plant and equipment, net		514.5				491.5
Goodwill and intangible assets, net		3,908.1				3,965.4
Other assets		531.8				516.6
Total assets		$	7,550.7			$	7,195.8
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Current portion of long-term debt		$	74.9			$	324.9
Accounts payable and accrued liabilities		798.2				728.3
Deferred revenue		182.9				186.1
Total current liabilities		1,056.0				1,239.3
Long-term debt, net of current portion		2,689.5				2,713.9
Deferred income taxes		189.4				201.8
Other long-term liabilities		346.8				333.5
Total Hologic stockholders' equity		3,267.9				2,705.2
Noncontrolling interest		1.1				2.1
Total liabilities and stockholders’ equity		$	7,550.7			$	7,195.8

HOLOGIC, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (in millions)
		Three Months Ended
		December 26, 2020					December 28, 2019
OPERATING ACTIVITIES
Net income		$	653.4				$	385.8
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation		21.1					21.6
Amortization of acquired intangibles		71.7					72.8
Stock-based compensation expense		18.6					18.1
Deferred income taxes		(12.0		)			(327.9		)
Intangible asset and equipment impairment charges		—					30.2
Debt extinguishment loss		21.6					—
Other adjustments and non-cash items		29.5					0.5
Changes in operating assets and liabilities, excluding the effect of acquisitions:
Accounts receivable		(175.5		)			17.6
Inventories		(21.2		)			(14.9		)
Prepaid income taxes		8.9					1.0
Prepaid expenses and other assets		(18.3		)			(2.6		)
Accounts payable		4.6					(55.4		)
Accrued expenses and other liabilities		58.1					(22.6		)
Deferred revenue		(10.5		)			(10.3		)
Net cash provided by operating activities		650.0					113.9
INVESTING ACTIVITIES
Acquisition of businesses, net of cash acquired		(4.9		)			(11.8		)
Capital expenditures		(32.4		)			(11.4		)
Increase in equipment under customer usage agreements		(12.4		)			(20.1		)
Purchase of insurance contracts		—					(2.4		)
Other activity		(0.2		)			—
Net cash used in investing activities		(49.9		)			(45.7		)
FINANCING ACTIVITIES
Repayments of long-term debt		(18.8		)			(9.4		)
Proceeds from senior notes		950.0					—
Repayment of senior notes		(970.8		)			—
Repayment under revolving credit line		(250.0		)			—
Proceeds from accounts receivable securitization agreement		—					16.0
Purchase of non-controlling interest		—					(1.4		)
Payment of deferred acquisition consideration		—					(16.6		)
Payment of debt issuance costs		(13.7		)			—
Repurchase of common stock		(101.3		)			(285.9		)
Proceeds from issuance of common stock pursuant to employee stock plans		23.3					18.7
Payment of minimum tax withholdings on net share settlements of equity awards		(46.4		)			(10.9		)
Payments under finance lease obligations		(0.5		)			(0.4		)
Net cash used in financing activities		(428.2		)			(289.9		)
Effect of exchange rate changes on cash and cash equivalents		(4.2		)			1.4
Net increase (decrease) in cash and cash equivalents		167.7					(220.3		)
Cash and cash equivalents, beginning of period		701.0					601.8
Cash and cash equivalents, end of period		$	868.7				$	381.5

HOLOGIC, INC. RECONCILIATION OF GAAP TO NON-GAAP RESULTS (Unaudited) (In millions, except earnings per share and margin percentages)
		Three Months Ended
		December 26, 2020					December 28, 2019
Gross Profit:
GAAP gross profit		$	1,180.4				$	433.8
Adjustments:
Amortization of acquired intangible assets (1)		61.6					63.6
Impairment of intangible assets and equipment (2)		—					25.8
Integration/consolidation costs (8)		0.3					—
Fair value write-up of acquired inventory sold (11)		0.9					0.3
Non-GAAP gross profit		$	1,243.2				$	523.5
Gross Margin Percentage:
GAAP gross margin percentage		73.3			%		51.0			%
Impact of adjustments above		3.9			%		10.6			%
Non-GAAP gross margin percentage		77.2			%		61.6			%
Operating Expenses:
GAAP operating expenses		$	294.9				$	309.0
Adjustments:
Amortization of acquired intangible assets (1)		(10.1		)			(9.1		)
Impairment of intangible assets and equipment (2)		—					(4.4		)
Transaction expenses (3)		(0.5		)			(2.0		)
Acquisition related adjustment (4)		—					3.8
MDR expenses (9)		(2.0		)			—
Contingent consideration adjustments (6)		(4.6		)			(0.9		)
Litigation settlements (7)		—					(0.7		)
Integration/consolidation costs (8)		(1.8		)			(5.5		)
Restructuring and divestiture charges (8)		(1.4		)			(0.9		)
Non-GAAP operating expenses		$	274.5				$	289.3
Operating Margin:
GAAP income from operations		$	885.5				$	124.8
Adjustments to gross profit as detailed above		62.8					89.7
Adjustments to operating expenses as detailed above		20.4					19.7
Non-GAAP income from operations		$	968.7				$	234.2
Operating Margin Percentage:
GAAP income from operations margin percentage		55.0			%		14.7			%
Impact of adjustments above		5.2			%		12.8			%
Non-GAAP operating margin percentage		60.2			%		27.5			%

Pre-Tax Income:
GAAP pre-tax income		$	832.4				$	97.4
Adjustments to pre-tax earnings as detailed above		83.2					109.4
Debt extinguishment loss (5)		21.6					—
Debt transaction costs (15)		5.8					—
Gain from SSI (14)		—					(1.5		)
Unrealized losses on forward foreign currency contracts (10)		14.0					3.0
Other (17)		—					1.1
Non-GAAP pre-tax income		$	957.0				$	209.4
Net Income Attributable to Hologic:
GAAP net income		$	653.4				$	385.8
Adjustments:
Amortization of acquired intangible assets (1)		71.7					72.7
Restructuring and integration/consolidation costs (8)		3.5					8.4
MDR expenses (9)		2.0					—
Impairment of intangible assets and equipment (2)		—					30.2
Acquisition related expenses and adjustments (3) (4) (11)		1.4					(3.5		)
Contingent consideration adjustment (6)		4.6					0.9
Litigation settlements (7)		—					0.7
Debt extinguishment loss and transaction costs (5) (15)		27.4					—
Gain from SSI (14)		—					(1.5		)
Non-operating charges (17) (10)		14.0					4.0
Discrete tax benefit from sale of Cynosure (16)		—					(312.2		)
Income tax effect of reconciling items (12)		(29.1		)			(21.6		)
Non-GAAP net income		$	748.9				$	163.9
Net loss attributable to non-controlling interest		(0.7		)			(0.2		)
Net income attributable to Hologic		$	749.6				$	164.1
Net Income Percentage:
GAAP net income percentage		40.6			%		45.4			%
Impact of adjustments above		6.0			%		(26.1		)	%
Non-GAAP net income attributable to Hologic percentage		46.6			%		19.3			%
Earnings Per Share Attributable to Hologic:
GAAP earnings per share - Diluted		$	2.50				$	1.43
Adjustment to net income (as detailed above)		0.36					(0.82		)
Non-GAAP earnings per share – diluted (13)		$	2.86				$	0.61
Adjusted EBITDA:
Non-GAAP net income		$	749.6				$	164.1
Interest expense, net, not adjusted above		21.9					30.7
Provision for income taxes		208.1					45.6
Depreciation expense, not adjusted above		21.1					21.5
Adjusted EBITDA		$	1,000.7				$	261.9

Explanatory Notes to Reconciliations:

(1)		To reflect non-cash expenses attributable to the amortization of acquired intangible assets.
(2)		To reflect recording the Cynosure business to fair value based upon meeting the assets-held-for-sale criteria in the first quarter of fiscal 2020 due to executing an agreement to sell the business.
(3)		To reflect expenses with third parties related to acquisitions and divestitures prior to when such transactions are completed. These expenses primarily comprise broker fees, legal fees, and consulting and due diligence fees.
(4)		To reflect an adjustment for the final Faxitron hold-back payment and an adjustment to reduce certain acquired accruals in fiscal 2020.
(5)		To reflect a debt extinguishment loss from refinancing the 2025 Senior Notes.
(6)		To reflect adjustments to the estimated contingent consideration liabilities related to the Acessa Health and Faxitron acquisitions in fiscal 2021 and 2020, respectively, which are payable upon meeting defined revenue growth metrics.
(7)		To reflect the Company's settlements of litigation.
(8)		To reflect restructuring and divestiture charges, and certain costs associated with the Company’s integration and facility consolidation plans, which primarily include retention and transfer costs, as well as costs incurred to integrate acquisitions and dispose businesses, including consulting, legal, tax and accounting fees. In addition, this category includes additional expenses incurred related to the Cynosure disposition and indemnification provisions for legal and tax matters that existed as of the date of disposition.
(9)		To reflect the exclusion of third party expenses incurred to obtain compliance with the European Medical Device Regulation requirement for the Company's existing products for which it already has FDA approval and/or CE mark.
(10)		To reflect non-cash unrealized gains and losses on the mark-to market on outstanding forward foreign currency and option contracts, which do not qualify for hedge accounting.
(11)		To reflect the fair value step up of inventory sold during the period related to the Acessa Health acquisition in fiscal 2021 and the SuperSonic Imagine and Health Beacons acquisitions in fiscal 2020, respectively.
(12)		To reflect an estimated annual effective tax rate of 21.75% for fiscal 2021 and fiscal 2020.
(13)		Non-GAAP earnings per share was calculated based on 261,785 and 269,721 weighted average diluted shares outstanding for the three months ended December 26, 2020 and December 28, 2019, respectively.
(14)		To reflect an adjustment to remeasure the Company's initial investment in SuperSonic Imagine pursuant to U.S. GAAP for purchase accounting.
(15)		To reflect the amount of debt issuance costs recorded directly to interest expense as a result of refinancing the 2025 Senior Notes.
(16)		To reflect a discrete tax benefit for the sale of Cynosure.
(17)		To reflect other non-operating activity.

Reconciliation of GAAP to non-GAAP EPS Guidance:

		Guidance Range
		Quarter Ending March 27, 2021
		Low				High
GAAP Net Income Per Share		$	2.34			$	2.46
Amortization of acquired intangible assets			0.27				0.27
Other charges			0.02				0.02
Tax Impact of Exclusions			(0.07	)			(0.07	)
Non-GAAP Net Income Per Share		$	2.56			$	2.68

		Trailing Twelve Months ended December 26, 2020
Return on Invested Capital:
Adjusted Net Operating Profit After Tax
Non-GAAP net income attributable to Hologic		$	1,638.8
Non-GAAP provision for income taxes		471.8
Non-GAAP interest expense		106.0
Non-GAAP other income		(11.4		)
Adjusted net operating profit before tax		$	2,205.2
Non-GAAP average effective tax rate (1)		22.4			%
Adjusted net operating profit after tax		$	1,710.7
Average Net Debt plus Average Stockholders’ Equity (2)
Average total debt		$	2,918.0
Less: Average cash and cash equivalents		(625.1		)
Average net debt		$	2,292.9
Average stockholders’ equity (3)		$	4,114.1
Average net debt plus average stockholders’ equity		$	6,407.0
Adjusted ROIC
Adjusted ROIC (adjusted net operating profit after tax above divided by average net debt plus average stockholders’ equity)		26.7			%

(1)		ROIC is presented on a TTM basis; non-GAAP effective tax rate for the three months ended March 28, 2020 was 23.8%, the three months ended June 27, 2020 was 22.75%, the three months ended September 26, 2020 was 22.75% and the three months ended December 26, 2020 was 21.75%.
(2)		Calculated using the average of the balances as of December 26, 2020 and December 28, 2019.
(3)		Adjusted (increased) to eliminate the effect of the impairment of intangible assets of $32.2 million in fiscal 2014, the impairment of goodwill of $685.7 million and an IPR&D asset of $46.0 million in fiscal 2018, the impairment of intangible assets and equipment of $685.4 million in fiscal 2019 and the impairment of intangible assets and equipment of $30.2 million in fiscal 2020. The impact of the intangible asset impairment charges is reflected net of tax.

		As of
		December 26, 2020
Net Leverage Ratio:
Total principal debt		$	2,793.9
Total cash		(868.7		)
Net principal debt, as adjusted		$	1,925.2
EBITDA for the last four quarters		$	2,296.5
Net Leverage Ratio		0.8

Other Supplemental Information:
		Three Months Ended
		December 26, 2020			December 28, \2019
Geographic Revenues
U.S.		70.7	%		74.4	%
Europe		21.0	%		12.9	%
Asia-Pacific		5.5	%		8.3	%
Rest of World		2.8	%		4.4	%
Total Revenues		100.0	%		100.0	%

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20210127005843/en/

FAQ

What were Hologic's Q1 2021 earnings results?

Hologic's Q1 2021 revenue was $1.61 billion, a 89.3% increase, with diluted EPS at $2.50.

What is the revenue guidance for Hologic in Q2 2021?

Hologic expects Q2 2021 revenue between $1.50 and $1.56 billion, indicating a potential 98.4% to 106.3% increase.

How did Hologic's molecular diagnostics revenue perform in Q1 2021?

Molecular diagnostics revenue reached $995.3 million, marking a 457.6% increase compared to the previous year.

What acquisitions did Hologic announce recently?

Hologic announced acquisitions of Biotheranostics for $230 million and SOMATEX Medical Technologies for $64 million.

How did Hologic's net margin change in Q1 2021?

Hologic's net margin decreased by 480 bps to 40.6% in Q1 2021.